Inicio › Linfoma › Massachusetts › Boston
Ensayos clínicos de Linfoma en Boston, MA
34 estudios para Linfoma buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
ReclutandoFase 1/2
- Call for Information (Investigational Site 0026), Boston
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ReclutandoFase 3
- Tufts Medical Center, Boston
HEME Home Transfusion Program
Reclutando
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Reclutando
- Mass General Hospital, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
ReclutandoFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
ReclutandoFase 1/2
- Research Site, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ReclutandoFase 3
- Research Site, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ReclutandoFase 1
- Beth Israel Deaconess Medical Center - Research, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Reclutando
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
ReclutandoFase 1/2
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
ReclutandoFase 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- Dana Farber Cancer Institute, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
ReclutandoFase 1/2
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ReclutandoEstudio observacional
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
Reclutando
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Reclutando
- Massachusetts General Hospital Cancer Center, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Reclutando
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
Odronextamab in Low Tumor Volume Advanced FL
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Reclutando
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
ReclutandoFase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
ReclutandoFase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
ReclutandoFase 2
- Dana Farber Cancer Institute, Boston
Más información sobre Linfoma en MedlinePlus
Ensayos de Linfoma en otras ciudades
- Houston, TX34 estudios
- New York City, NY33 estudios
- Washington, DC23 estudios
- Baldwin Park, CA22 estudios
- Chicago, IL19 estudios
- Durham, NC17 estudios
- St. Louis, MO15 estudios
- Cleveland, OH13 estudios
- Seattle, WA13 estudios
- Atlanta, GA13 estudios
- Philadelphia, PA13 estudios
- Edison, NJ12 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer (todos los tipos)90 estudios
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer de pulmón63 estudios
- Cáncer del colon y del recto62 estudios
- Cáncer de ovario62 estudios
- Cáncer metastásico61 estudios
- Cáncer de próstata56 estudios
- Cáncer de endometrio51 estudios
- Depresión50 estudios
- Fallo cardíaco46 estudios
- Mieloma múltiple45 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.